Log in

Relevant bibliographies by topics / Drug analysis / Journal articles

Journal articles on the topic 'Drug analysis'

To see the other types of publications on this topic, follow the link: Drug analysis.

Author: Grafiati

Published: 4 June 2021

Last updated: 27 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Drug analysis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sriwijitalai, Won, and Viroj Wiwanitkit. "Drug–drug interaction analysis: Antituberculosis drugs versus antiretroviral drugs." Biomedical and Biotechnology Research Journal (BBRJ) 3, no. 2 (2019): 101. http://dx.doi.org/10.4103/bbrj.bbrj_52_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Shumyantseva, V. V., T. V. Bulko, and P. I. Koroleva. "Drug Analysis Methods." Biomedical Chemistry: Research and Methods 2, no. 4 (2019): e00110. http://dx.doi.org/10.18097/bmcrm00110.

Full text

Abstract:

Modern methods of analysis of drugs for their quantitative assessment are considered. Particular attention is paid to the electrochemical methods of drug registration, based on the reaction of electrooxidation of molecules. Systems and materials for modifying electrodes are described, as well as methods for producing modified electrodes for electrochemical reactions on the surface of electrodes. The authors present data on the electroanalysis of acetaminophen, diclofenac, ibuprofen, omeprazole, using electrodes modified with carbon nanomaterials based on carbon nanotubes and graphene. It was shown that electroanalytical methods allow the registration of therapeutic drugs in a wide range of detectable concentrations (0.1 μМ - 10 mM), which can be used to work with biological fluids (plasma, blood, urine), to conduct drug monitoring and study drug-drug interactions.

APA, Harvard, Vancouver, ISO, and other styles

3

Görög, Sándor. "Drug safety, drug quality, drug analysis." Journal of Pharmaceutical and Biomedical Analysis 48, no. 2 (September 2008): 247–53. http://dx.doi.org/10.1016/j.jpba.2007.10.038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Singh, Anil Kumar. "Drug analysis." Brazilian Journal of Pharmaceutical Sciences 47, no. 1 (March 2011): 194. http://dx.doi.org/10.1590/s1984-82502011000100026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Görög, S. "Drug analysis." TrAC Trends in Analytical Chemistry 11, no. 7 (August 1992): vi—vii. http://dx.doi.org/10.1016/0165-9936(92)87052-l.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mohd Ali, Yousoff Effendy, Kiam Heong Kwa, and Kurunathan Ratnavelu. "Predicting new drug indications from network analysis." International Journal of Modern Physics C 28, no. 09 (September 2017): 1750118. http://dx.doi.org/10.1142/s0129183117501182.

Full text

Abstract:

This work adapts centrality measures commonly used in social network analysis to identify drugs with better positions in drug-side effect network and drug-indication network for the purpose of drug repositioning. Our basic hypothesis is that drugs having similar phenotypic profiles such as side effects may also share similar therapeutic properties based on related mechanism of action and vice versa. The networks were constructed from Side Effect Resource (SIDER) 4.1 which contains 1430 unique drugs with side effects and 1437 unique drugs with indications. Within the giant components of these networks, drugs were ranked based on their centrality scores whereby 18 prominent drugs from the drug-side effect network and 15 prominent drugs from the drug-indication network were identified. Indications and side effects of prominent drugs were deduced from the profiles of their neighbors in the networks and compared to existing clinical studies while an optimum threshold of similarity among drugs was sought for. The threshold can then be utilized for predicting indications and side effects of all drugs. Similarities of drugs were measured by the extent to which they share phenotypic profiles and neighbors. To improve the likelihood of accurate predictions, only profiles such as side effects of common or very common frequencies were considered. In summary, our work is an attempt to offer an alternative approach to drug repositioning using centrality measures commonly used for analyzing social networks.

APA, Harvard, Vancouver, ISO, and other styles

7

Aydin, Elif Burcu, Muhammet Aydin, and Mustafa Kemal Sezginturk. "Biosensors in Drug Discovery and Drug Analysis." Current Analytical Chemistry 15, no. 4 (July 3, 2019): 467–84. http://dx.doi.org/10.2174/1573411014666180912131811.

Full text

Abstract:

Background: The determination of drugs in pharmaceutical formulations and human biologic fluids is important for pharmaceutical and medical sciences. Successful analysis requires low sensitivity, high selectivity and minimum interference effects. Current analytical methods can detect drugs at very low levels but these methods require long sample preparation steps, extraction prior to analysis, highly trained technical staff and high-cost instruments. Biosensors offer several advantages such as short analysis time, high sensitivity, real-time analysis, low-cost instruments, and short pretreatment steps over traditional techniques. Biosensors allow quantification not only of the active component in pharmaceutical formulations, but also the degradation products and metabolites in biological fluids. The present review gives comprehensive information on the application of biosensors for drug discovery and analysis. Moreover, this review focuses on the fabrication of these biosensors. Methods: Biosensors can be classified as the utilized bioreceptor and the signal transduction mechanism. The classification based on signal transductions includes electrochemical optical, thermal or acoustic. Electrochemical and optic transducers are mostly utilized transducers used for drug analysis. There are many biological recognition elements, such as enzymes, antibodies, cells that have been used in fabricating of biosensors. Aptamers and antibodies are the most widely used recognition elements for the screening of the drugs. Electrochemical sensors and biosensors have several advantages such as low detection limits, a wide linear response range, good stability and reproducibility. Optical biosensors have several advantages such as direct, real-time and label-free detection of many biological and chemical substances, high specificity, sensitivity, small size and low cost. Modified electrodes enhance sensitivity of the electrodes to develop a new biosensor with desired features. Chemically modified electrodes have gained attention in drug analysis owing to low background current, wide potential window range, simple surface renewal, low detection limit and low cost. Modified electrodes produced by modifying of a solid surface electrode via different materials (carbonaceous materials, metal nanoparticles, polymer, biomolecules) immobilization. Recent advances in nanotechnology offer opportunities to design and construct biosensors. Unique features of nanomaterials provide many advantages in the fabrication of biosensors. Nanomaterials have controllable chemical structures, large surface to volume ratios, functional groups on their surface. To develop proteininorganic hybrid nanomaterials, four preparation methods have been used. These methods are immobilization, conjugation, crosslinking and self-assembly. In the present manuscript, applications of different biosensors, fabricated by using several materials, for drug analysis are reviewed. The biosensing strategies are investigated and discussed in detail. Results: Several analytical techniques such as chromatography, spectroscopy, radiometry, immunoassays and electrochemistry have been used for drug analysis and quantification. Methods based on chromatography require timeconsuming procedure, long sample-preparation steps, expensive instruments and trained staff. Compared to chromatographic methods, immunoassays have simple protocols and lower cost. Electrochemical measurements have many advantages over traditional chemical analyses and give information about drug quantity, metabolic fate of drugs, and pharmacological activity. Moreover, the electroanalytical methods are useful to determine drugs sensitively and selectivity. Additionally, these methods decrease analysis cost and require low-cost instruments and simple sample pretreatment steps. Conclusion: In recent years, drug analyses are performed using traditional techniques. These techniques have a good detection limit, but they have some limitations such as long analysis time, expensive device and experienced personnel requirement. Increased demand for practical and low-cost analytical techniques biosensor has gained interest for drug determinations in medical sciences. Biosensors are unique and successful devices when compared to traditional techniques. For drug determination, different electrode modification materials and different biorecognition elements are used for biosensor construction. Several biosensor construction strategies have been developed to enhance the biosensor performance. With the considerable progress in electrode surface modification, promotes the selectivity of the biosensor, decreases the production cost and provides miniaturization. In the next years, advances in technology will provide low cost, sensitive, selective biosensors for drug analysis in drug formulations and biological samples.

APA, Harvard, Vancouver, ISO, and other styles

8

Kirilochev, Oleg O., Inna P. Dorfman, Adelya R. Umerova, and Svetlana E. Bataeva. "Potential drug-drug interactions in the psychiatric hospital: Frequency analysis." Research Results in Pharmacology 5, no. 4 (December 12, 2019): 1–6. http://dx.doi.org/10.3897/rrpharmacology.5.39681.

Full text

Abstract:

Introduction: Drug-drug interactions are an important clinical problem in pharmacotherapy. This study is focused on different types of drugs used in a psychiatric hospital. Materials and methods: The pharmacoepidemiological study included the analysis of medical records of 500 psychiatric inpatients. The patients were divided into 2 groups: under 65 and over 65 years of age. All the drug prescriptions were analyzed to identify the combinations of drugs that can induce drug-drug interactions and determine their clinical significance. Results and discussion: Over 77% of hospitalized patients were administered drug combinations that could induce drug-drug interactions, most of which were of moderate clinical significance. A reliable association was found between the patient’s age, the clinical significance of drug-drug interactions, and the pharmacotherapy structure. The most common irrational drug combinations were identified. Conclusion: Timely analysis of drug prescriptions for potential drug-drug interactions can enhance the safety of pharmacotherapy and decrease the risk of adverse drug reactions in the psychiatric inpatient setting.

APA, Harvard, Vancouver, ISO, and other styles

9

Kumar Shukla, Ajay, Kumar Shukla, Rekha Mehani, Swati Jain, and Sheema Maqsood. "Analysis of FDA Novel Drug Approvals." Biomedical and Pharmacology Journal 14, no. 1 (March 28, 2021): 225–33. http://dx.doi.org/10.13005/bpj/2117.

Full text

Abstract:

Background: United States Food and Drug Administration (FDA) is the fastest drug review agency in the world. FDA is responsible for the protection of public health by assuring that foods are safe, wholesome, sanitary and, properly labeled. Novel drug Approvals are usually innovative products to serve unmet medical needs or otherwise help to advance patient care. Methods: FDA novel drug approvals were analyzed from calendar year (CY) 2012 to 2018 based on not only their numbers but also BASED ON their impact, innovation, access, and predictability. Results: The total number of novel drugs approved from CY 2012 to 2018 was 279 (average 40 novel drugs/ year). Impact of novel drug approvals: 50% were first in class and 43% were for rare diseases. Overall expedited development and review methods were used in 63% of the novel drug approvals. Access of novel drug approvals: 84% were first-cycle approval, 74% were approved in the US before other countries, 58% priority reviews among novel drug approvals. Predictability of novel drug approvals: 98% approvals able to meet PDUFA goal dates for application review. Conclusions: Novel drug approvals during CY 2012-2018 had a high quality which is very much evident by their high impact, good access, and high predictability.

APA, Harvard, Vancouver, ISO, and other styles

10

Patel, Priyanka V. "DRUG REGULATION IN INDIA: SWOT ANALYSIS." International Journal of Drug Regulatory Affairs 3, no. 3 (February 13, 2018): 21–27. http://dx.doi.org/10.22270/ijdra.v3i3.168.

Full text

Abstract:

Drug regulation plays pivotal role in any country because the purpose of drug regulation is to promote and to protect public health by ensuring the safety, efficacy and quality of drugs. Drug regulation should cover all products for which medicinal claims are made and all aspects of drugs like manufacturing, import, export, distribution, dispensing, promotion, sell and supply. But unfortunately drug regulation does not meet these requirements in India as legislation omits or exempts certain areas of pharmaceutical activity from the scope of control in India. Although there are so many deficiencies, lacunae and hurdles in Indian drug regulation, there is a wider scope for drug regulation in India because government is taking positive steps to reform it. One can say India is a vast ocean of opportunities. Hence it is tried to analyse the drug regulation of India using the framework of SWOT (Strengths, Weaknesses, Opportunities, Threats). SWOT analysis aids to find out possible ways to overcome the weaknesses and threats, and to utilize the strengths and opportunities properly

APA, Harvard, Vancouver, ISO, and other styles

11

Gross, Franz H. "Drug Utilization Data in Risk/Benefit Analyses of Drugs-Benefit Analysis." Acta Medica Scandinavica 215, S683 (April 24, 2009): 141–47. http://dx.doi.org/10.1111/j.0954-6820.1984.tb08730.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Harborne, Jeffrey B. "Plant drug analysis." Phytochemistry 24, no. 8 (January 1985): 1873. http://dx.doi.org/10.1016/s0031-9422(00)82581-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Harborne, Jeffrey B. "Plant drug analysis." Phytochemistry 44, no. 8 (April 1997): 1596–97. http://dx.doi.org/10.1016/s0031-9422(97)80771-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Fong, Harry H. S. "Plant Drug Analysis." Journal of Pharmaceutical Sciences 75, no. 8 (August 1986): 829–30. http://dx.doi.org/10.1002/jps.2600750841.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Johnson, C. A. "Drug analysis—Why?" Journal of Pharmaceutical and Biomedical Analysis 4, no. 6 (January 1986): 689–96. http://dx.doi.org/10.1016/0731-7085(86)80080-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Wong, SK. "Analysis of Drug Overdose in Teenagers." Hong Kong Journal of Emergency Medicine 9, no. 3 (July 2002): 145–49. http://dx.doi.org/10.1177/102490790200900305.

Full text

Abstract:

This is a retrospective study to analyze the pattern of drug overdose in teenagers. Between 1/7/98 to 30/6/01, there were 100 patients between the age of 13 to 19 attending Alice Ho Miu Ling Nethersole Hospital emergency department for drug overdose. Eighty-three cases were included for analysis. The majority was female (71 cases, 86%). The most frequent drugs were panadol and drugs for treatment of flu (43%), sleeping pills (18%), diazepam (18%). Panadol, drugs for treatment of flu and sleeping pills were usually bought over the counter. Diazepam was obtained from friends or bought in China. The common reasons for drug overdose were “unhappy boyfriend/girlfriend relationship” (40%), “unhappy relationship with family” (25%), “unhappiness at school” (14%). Thirty-one percent of cases had suicidal ideas. Many of them had poor family relationships, poor school performance or were unemployed.

APA, Harvard, Vancouver, ISO, and other styles

17

Liljestrand, Åke. "Drug Utilization Data in Benefit Analysis of Drugs." Acta Medica Scandinavica 215, S683 (April 24, 2009): 135–39. http://dx.doi.org/10.1111/j.0954-6820.1984.tb08729.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Wang, Junmei, and Tingjun Hou. "Drug and Drug Candidate Building Block Analysis." Journal of Chemical Information and Modeling 50, no. 1 (December 18, 2009): 55–67. http://dx.doi.org/10.1021/ci900398f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Yu, Donghui, Bertrand Blankert, Jean‐Claude Viré, and Jean‐Michel Kauffmann. "Biosensors in Drug Discovery and Drug Analysis." Analytical Letters 38, no. 11 (August 1, 2005): 1687–701. http://dx.doi.org/10.1080/00032710500205659.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Shipman, Charles. "Analysis of drug-drug interactions: an overview." Antiviral Research 29, no. 1 (January 1996): 41–43. http://dx.doi.org/10.1016/0166-3542(95)00913-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Ares, Ana, and José Bernal. "Hydrophilic interaction chromatography in drug analysis." Open Chemistry 10, no. 3 (June 1, 2012): 534–53. http://dx.doi.org/10.2478/s11532-012-0003-8.

Full text

Abstract:

AbstractHydrophilic interaction chromatography (HILIC) is an increasingly popular alternative to conventional HPLC for drug analysis. It offers increased selectivity and sensitivity, and improved efficiency when quantifying drugs and related compounds in complex matrices such as biological and environmental samples, pharmaceutical formulations, food, and animal feed. In this review we summarize HILIC methods recently developed for drug analysis (2006–2011). In addition, a list of important applications is provided, including experimental conditions and a brief summary of results. The references provide a comprehensive overview of current HILIC applications in drug analysis.

APA, Harvard, Vancouver, ISO, and other styles

22

Arroyo, Monica M., Alberto Berral-González, Santiago Bueno-Fortes, Diego Alonso-López, and Javier De Las Rivas. "Mining Drug-Target Associations in Cancer: Analysis of Gene Expression and Drug Activity Correlations." Biomolecules 10, no. 5 (April 25, 2020): 667. http://dx.doi.org/10.3390/biom10050667.

Full text

Abstract:

Cancer is a complex disease affecting millions of people worldwide, with over a hundred clinically approved drugs available. In order to improve therapy, treatment, and response, it is essential to draw better maps of the targets of cancer drugs and possible side interactors. This study presents a large-scale screening method to find associations of cancer drugs with human genes. The analysis is focused on the current collection of Food and Drug Administration (FDA)-approved drugs (which includes about one hundred chemicals). The approach integrates global gene-expression transcriptomic profiles with drug-activity profiles of a set of 60 human cell lines obtained for a collection of chemical compounds (small bioactive molecules). Using a standardized expression for each gene versus standardized activity for each drug, Pearson and Spearman correlations were calculated for all possible pairwise gene-drug combinations. These correlations were used to build a global bipartite network that includes 1007 gene-drug significant associations. The data are integrated into an open web-tool called GEDA (Gene Expression and Drug Activity) which includes a relational view of cancer drugs and genes, disclosing the putative indirect interactions found for FDA-approved drugs as well as the known targets of these drugs. The results also provide insight into the complex action of pharmaceuticals, presenting an alternative view to address predicted pleiotropic effects of the drugs.

APA, Harvard, Vancouver, ISO, and other styles

23

Kuo, Ping-Chung. "Food and Drug Analysis." Molecules 25, no. 10 (May 21, 2020): 2403. http://dx.doi.org/10.3390/molecules25102403.

Full text

Abstract:

Food can be regarded as functional if it beneficially affects one or more target functions in the body in a way that is relevant to either the state of well-being and health or to the reduction of the risk of a disease [...]

APA, Harvard, Vancouver, ISO, and other styles

24

Ruebben, Alexander, Juergen Boeing, and Norbert Weiss. "Drug-eluting Balloon Analysis." Interventional Cardiology Review 5, no. 1 (2010): 74. http://dx.doi.org/10.15420/icr.2010.5.1.74.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Ruebben, Alexander, Juergen Boeing, and Norbert Weiss. "Drug-eluting Balloon Analysis." Interventional Cardiology Review 6, no. 1 (2011): 56. http://dx.doi.org/10.15420/icr.2011.6.1.56.

Full text

Abstract:

Although different drug-eluting balloons appear similar in the underlying concept, the technical differences are important. This article takes a closer look at the coating technique and applications of the different products in the market and why different techniques have been used. The main points covered are loading dose, excipient used and homogenous or partial drug coverage of the balloon used.

APA, Harvard, Vancouver, ISO, and other styles

26

Hart, Linda L., Robert K. Middleton, and Kellie D. McQueen. "Drug Information Analysis Service." DICP 24, no. 6 (June 1990): 597–600. http://dx.doi.org/10.1177/106002809002400609.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Hart, Linda L., Robert K. Middleton, and Daniel L. Wandres. "Drug Information Analysis Service." DICP 25, no. 1 (January 1991): 30–35. http://dx.doi.org/10.1177/106002809102500107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Hart, Linda L., Robert K. Middleton, and Daniel L. Wandres. "Drug Information Analysis Service." DICP 25, no. 5 (May 1991): 473–77. http://dx.doi.org/10.1177/106002809102500507.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Hart, Linda L., Robert K. Middleton, and Daniel L. Wandres. "Drug Information Analysis Service." DICP 25, no. 6 (June 1991): 606–12. http://dx.doi.org/10.1177/106002809102500609.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Hart, Linda L., Robert K. Middleton, and Daniel L. Wandres. "Drug Information Analysis Service." DICP 25, no. 7-8 (July 1991): 747–54. http://dx.doi.org/10.1177/106002809102500711.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Hart, Linda L., Robert K. Middleton, and Daniel L. Wandres. "Drug Information Analysis Service." DICP 25, no. 9 (September 1991): 941–47. http://dx.doi.org/10.1177/106002809102500908.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Hart, Linda L., Robert K. Middleton, and Daniel L. Wandres. "Drug Information Analysis Service." DICP 25, no. 10 (October 1991): 1076–80. http://dx.doi.org/10.1177/106002809102501011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Hart, Linda L., and Karen C. Hobdy-Henderson. "Drug Information Analysis Service." DICP 25, no. 11 (November 1991): 1185–89. http://dx.doi.org/10.1177/106002809102501107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Hart, Linda L., and Karen C. Hobdy-Henderson. "Drug Information Analysis Service." DICP 25, no. 12 (December 1991): 1339–43. http://dx.doi.org/10.1177/106002809102501212.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Hobdy-Henderson, Karen C. "Drug Information Analysis Service." Annals of Pharmacotherapy 26, no. 1 (January 1992): 36–41. http://dx.doi.org/10.1177/106002809202600110.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Hart, Linda L., and Karen C. Hobdy-Henderson. "Drug Information Analysis Service." Annals of Pharmacotherapy 26, no. 2 (February 1992): 213–17. http://dx.doi.org/10.1177/106002809202600216.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Hart, Linda L., and Karen C. Hobdy-Henderson. "Drug Information Analysis Service." Annals of Pharmacotherapy 26, no. 3 (March 1992): 344–49. http://dx.doi.org/10.1177/106002809202600308.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Hart, Linda L., and Karen C. Hobdy-Henderson. "Drug Information Analysis Service." Annals of Pharmacotherapy 26, no. 6 (June 1992): 784–88. http://dx.doi.org/10.1177/106002809202600609.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Hart, Linda L., and Karen C. Hobdy-Henderson. "Drug Information Analysis Service." Annals of Pharmacotherapy 26, no. 7-8 (July 1992): 932–38. http://dx.doi.org/10.1177/106002809202600717.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Hart, Linda L., and Karen C. Hobdy-Henderson. "Drug Information Analysis Service." Annals of Pharmacotherapy 26, no. 9 (September 1992): 1094–98. http://dx.doi.org/10.1177/106002809202600911.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Hart, Linda L., Donna J. Schroeder, Susan L. Miyagl, Mike Woodward, and Mary Lea Gora. "Drug Information Analysis Service." Annals of Pharmacotherapy 27, no. 2 (February 1993): 188–89. http://dx.doi.org/10.1177/106002809302700212.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Schneiderhan, Mark E. "Drug Information Analysis Service." Annals of Pharmacotherapy 27, no. 3 (March 1993): 311–13. http://dx.doi.org/10.1177/106002809302700312.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Schroeder, Donna J., Linda L. Hart, and Susan L. Miyagi. "Drug Information Analysis Service." Annals of Pharmacotherapy 27, no. 4 (April 1993): 447–49. http://dx.doi.org/10.1177/106002809302700411.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Schroeder, Donna J., Linda L. Hart, and Susan L. Miyagi. "Drug Information Analysis Service." Annals of Pharmacotherapy 27, no. 5 (May 1993): 589–93. http://dx.doi.org/10.1177/106002809302700513.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Schroeder, Donna J., Linda L. Hart, and Susan L. Miyagi. "Drug Information Analysis Service." Annals of Pharmacotherapy 27, no. 6 (June 1993): 732–35. http://dx.doi.org/10.1177/106002809302700613.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Schroeder, Donna J., Linda L. Hart, and Susan L. Miyagi. "Drug Information Analysis Service." Annals of Pharmacotherapy 27, no. 7-8 (July 1993): 892–97. http://dx.doi.org/10.1177/106002809302700717.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Schroeder, Donna J., Linda L. Hart, and Shalini S. Lynch. "Drug Information Analysis Service." Annals of Pharmacotherapy 27, no. 12 (December 1993): 1470–77. http://dx.doi.org/10.1177/106002809302701213.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Schroeder, Donna J., and Shalini S. Lynch. "Drug Information Analysis Service." Annals of Pharmacotherapy 28, no. 9 (September 1994): 1038–44. http://dx.doi.org/10.1177/106002809402800909.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Schroeder, Donna J., and Candy Tsourounis. "Drug Information Analysis Service." Annals of Pharmacotherapy 28, no. 11 (November 1994): 1245–49. http://dx.doi.org/10.1177/106002809402801107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Schroeder, Donna J., and Candy Tsourounis. "Drug Information Analysis Service." Annals of Pharmacotherapy 28, no. 12 (December 1994): 1353–58. http://dx.doi.org/10.1177/106002809402801206.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!